| FFLDX | TRRNX | FFLDX / TRRNX | |
| Total Expense Ratio | 0.08 | 0.63 | 13% |
| Annual Report Gross Expense Ratio | 0.08 | 0.63 | 13% |
| Fund Existence | 11 years | 20 years | - |
| Gain YTD | 9.753 | 10.290 | 95% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 5000000 | 2500 | 200,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 24.4B | 12B | 203% |
| Annual Yield % from dividends | 1.71 | 1.14 | 149% |
| Returns for 1 year | 18.98 | 15.78 | 120% |
| Returns for 3 years | 57.40 | 46.73 | 123% |
| Returns for 5 years | 53.81 | 27.46 | 196% |
| Returns for 10 years | 144.78 | 107.29 | 135% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GTHIX | 40.70 | 0.54 | +1.34% |
| Invesco Health Care Invstor | |||
| AAGOX | 115.05 | N/A | N/A |
| Alger Large Cap Growth I-2 | |||
| GSPKX | 19.88 | N/A | N/A |
| Goldman Sachs US Eq Div and Prem Instl | |||
| RNNEX | 76.91 | -0.98 | -1.26% |
| American Funds New Economy R-2E | |||
| MCYAX | 15.47 | -0.62 | -3.85% |
| NYLI Candriam Emerging Markets Eq Cl A | |||